Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19
Launched by DUKE UNIVERSITY · Apr 20, 2020
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
A secondary aim will be to evaluate the rates of acute care during COVID-19 with telehealth in comparison to the rates during our prior Quality Improvement (QI) project (NCT04277650), considering the risk prediction based on our previously developed ML algorithm. Patient risk during this period will be assessed by the ML algorithm and actual rates of Emergency Department visits and hospitalizations (acute encounters) will be compared to the results of our prior QI project. These data will be used to discern how actual rates of acute care compare to providers' expectations both with and with...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • started outpatient radiation therapy with or without concurrent systemic therapy at Duke Cancer Center during the COVID-19 outbreak
- Exclusion Criteria:
- • undergoing total body radiation therapy for hematopoetic stem cell transplantation
- • undergoing therapy as inpatient
- • completed radiation therapy prior to algorithm execution
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Manisha Palta, MD
Principal Investigator
Duke Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials